Investors always keep an eye on employment-related numbers during the first week of the month, and today's news from the private sector pointed to healthy job creation that raised hopes of a spring thaw for the U.S. economy. The S&P 500 climbed to another record even as the Dow fell just short with a 40-point gain, but gains for Tesla Motors (NASDAQ:TSLA), Acceleron Pharma (NASDAQ:XLRN), and Ballard Power Systems (NASDAQ:BLDP) were much more substantial than the broader market's rise Wednesday.
Tesla rose 6% on news that it has appealed amendments to regulations from the New Jersey Motor Vehicle Commission that would prevent it from selling vehicles directly to customers within the state rather than going through established dealers with franchise agreements. With at least one measure proposed by a state lawmaker that would allow Tesla to use its direct-sales model in New Jersey, it's clear that the stakes are high for both the New Jersey state government and for Tesla. Although the state doesn't want to alienate its dealership constituency, the prospect of slamming the door on the popular high-growth electric-car company doesn't make for smart politics either. Today's stock gain suggests that investors think the issue will get a favorable resolution in the long run.
Acceleron Pharma climbed 13% after an SEC filing revealed that biotech giant Celgene (NASDAQ:CELG) has agreed to spend $47 million to buy 1.1 million shares of Acceleron stock from five pre-IPO investors in the company, including Britain's Alkermes (NASDAQ:ALKS). Celgene already owns a substantial stake in Acceleron, but after the purchase, its position is expected to rise to nearly 15%. Much of Acceleron's future depends on its partnership with Celgene, which includes splitting development costs of candidate drugs sotatercept and ACE-536. With studies still ongoing, it's too early to tell whether Acceleron will prove to be a good investment for Celgene and other shareholders.
Ballard Power Systems gained 8% as the fuel-cell maker said that buses using Ballard's fuel-cell modules were delivered to Aberdeen, Scotland as part of the city's hydrogen bus project. The buses were manufactured by Van Hool, a leading bus-maker in Europe, and Ballard expects the buses to go into use next month. Ballard's presence in Europe is still relatively small, with about 40 buses expected to have Ballard fuel cells in 2014. But investors hope that economies of scale will make Ballard's systems more competitive and drive future demand.
Dan Caplinger has no position in any stocks mentioned. The Motley Fool recommends Celgene and Tesla Motors and owns shares of Tesla Motors. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Why Juno Therapeutics Stock Is Soaring Today
The pharmaceutical industry's long-anticipated consolidation of CAR-T biotech companies may be starting.
Will 2018 Be Celgene Corporation's Best Year Yet?
The answer is yes. And no.
Here's What Celgene's Management Just Said About Its Future
An optimistic outlook could spark interest in the large-cap biotech's shares.